Indicated as monotherapy for Older people with HR-beneficial, HER2-unfavorable Sophisticated or metastatic breast most cancers with condition development subsequent endocrine therapy and prior chemotherapy in metastatic location 200 mg PO BID duvelisib will raise the degree or influence of abemac